# RAMP 203 (NCT05074810)

> Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

No report yet. It can be ordered.

- Drugs tested: avutometinib plus sotorasib; avutometinib plus sotorasib plus defactinib
- Indication: KRAS G12C mutant non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05074810
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Verastem, Inc.
- Conditions: Non Small Cell Lung Cancer; KRAS Activating Mutation
- Interventions: avutometinib and sotorasib; avutometinib and sotorasib and defactinib
- Enrollment: 153
- Primary outcome: Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib
- Primary outcome: Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A

## Indexed commentary on RAMP 203 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ramp-203-nct05074810